ID: ALA432737

Max Phase: Preclinical

Molecular Formula: C30H35NO6

Molecular Weight: 505.61

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccc(C(OCCN2CCCC(C(=O)O)C2)(c2ccc(OC)cc2)c2ccc(OC)cc2)cc1

Standard InChI:  InChI=1S/C30H35NO6/c1-34-26-12-6-23(7-13-26)30(24-8-14-27(35-2)15-9-24,25-10-16-28(36-3)17-11-25)37-20-19-31-18-4-5-22(21-31)29(32)33/h6-17,22H,4-5,18-21H2,1-3H3,(H,32,33)

Standard InChI Key:  VDLDUZLDZBVOAS-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 505.61

Molecular Weight (Monoisotopic): 505.2464

AlogP: 4.82

#Rotatable Bonds: 11

Polar Surface Area: 77.46

Molecular Species: ZWITTERION

HBA: 6

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 7

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 3.11

CX Basic pKa: 9.04

CX LogP: 2.33

CX LogD: 2.32

Aromatic Rings: 3

Heavy Atoms: 37

QED Weighted: 0.37

Np Likeness Score: -0.45

References

1. Dhar TG, Borden LA, Tyagarajan S, Smith KE, Branchek TA, Weinshank RL, Gluchowski C..  (1994)  Design, synthesis and evaluation of substituted triarylnipecotic acid derivatives as GABA uptake inhibitors: identification of a ligand with moderate affinity and selectivity for the cloned human GABA transporter GAT-3.,  37  (15): [PMID:8057281] [10.1021/jm00041a012]

2. Singh K, Kumar P, Bhatia R, Mehta V, Kumar B, Akhtar MJ..  (2022)  Nipecotic acid as potential lead molecule for the development of GABA uptake inhibitors; structural insights and design strategies.,  234  [PMID:35306287] [10.1016/j.ejmech.2022.114269]

Source

Source(1):

• Scientific Literature